Loading
Rilvegostomig / Non Squamous Non Small Cell Lung Cancer / Cisplatin · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 trial registration comparing rilvegostomig (an investigational agent) to pembrolizumab, each combined with platinum-based chemotherapy, in first-line treatment of PD-L1-expressing locally advanced or metastatic non-squamous NSCLC. No efficacy or safety results are posted in this registry record; the trial is actively recruiting. The reader should await peer-reviewed publication of results before drawing clinical conclusions.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Non-squamous Non-small Cell Lung Cancer; age from 18 Years. Intervention: Arm A. Compared with: Arm B — Active Comparator. n = 1,160. 295 sites across 25 countries.
This is a Phase 3 trial registration comparing rilvegostomig (an investigational agent) to pembrolizumab, each combined with platinum-based chemotherapy, in first-line treatment of PD-L1-expressing locally advanced or metastatic non-squamous NSCLC. No efficacy or safety results are posted in this registry record; the trial is actively recruiting. The reader should await peer-reviewed publication of results before drawing clinical conclusions.
Efficacy and safety data are not reported; conclusions cannot be drawn from this source.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no results posted; it describes a planned study of investigational therapy in advanced NSCLC, currently recruiting.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06627647). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1160 participants (ESTIMATED). Conditions: Non-squamous Non-small Cell Lung Cancer. Interventions: DRUG: Rilvegostomig; DRUG: Pembrolizumab; DRUG: Carboplatin; DRUG: Cisplatin; DRUG: Pemetrexed. Primary outcome measures: Overall survival (OS) , Up to approximately 6 years; Progression-free survival (PFS) , Up to approximately 6 years. Brief summary: The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.